SC
BMY icon

Stance Capital’s Bristol-Myers Squibb BMY Stock Holding History

Stance Capital’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.11M Buy
84,197
+56,895
+208% +$3.32M 2.48% 3
2025
Q4 		$1.47M Sell
27,302
-7,689
-22% -$370K 0.54% 48
2025
Q3 		$1.58M Buy
34,991
+1,796
+5% +$83.9K 0.58% 41
2025
Q2 		$1.54M Sell
33,195
-9,170
-22% -$450K 0.58% 54
2025
Q1 		$2.58M Buy
42,365
+39,165
+1,224% +$2.28M 1.91% 27
2024
Q4 		$181K Buy
+3,200
New +$179K 0.11% 86

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stance Capital's BMY Position: Q1 2026 in Review

Stance Capital increased its Bristol-Myers Squibb (BMY) stake by 208% in Q1 2026, buying an estimated $3.32M and bringing the position to 84,197 shares worth $5.11M. The position accounts for 2.48% of the portfolio, ranked #3.

Stance Capital first reported a position in BMY in Q4 2024 and has held it in 6 quarters since. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Stance Capital held 84,197 shares of Bristol-Myers Squibb worth $5.11M as of Q1 2026.
  • Stance Capital bought 56,895 Bristol-Myers Squibb shares in Q1 2026, an estimated $3.32M.
  • Bristol-Myers Squibb made up 2.48% of Stance Capital's portfolio in Q1 2026, its #3 holding.
  • Stance Capital first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 6 quarters since.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Stance Capital's 13F filing for Q1 2026, filed 14 May 2026.